吡非尼酮治疗IPF的预后与预测生物标志物:CAPACITY和ASCEND试验事后分析
该研究对CAPACITY和ASCEND试验进行事后分析,评估血浆蛋白生物标志物在IPF中的预后和预测价值。
要点
- 基线CCL18是IPF疾病进展最一致的预测生物标志物。
- 吡非尼酮治疗获益不受基线生物标志物浓度影响。
- CCL18潜在可用于新靶点发现和临床试验设计。
核心结论
- 血CCL18浓度是跨IPF队列最一致的疾病进展预测指标,可能有助于新靶点发现和临床试验设计。
研究设计与样本
- 对CAPACITY 004、CAPACITY 006和ASCEND试验进行事后分析,设测试队列和复制队列。
- 纳入40-80岁IPF患者,接受吡非尼酮2403 mg/天或安慰剂,基线生物标志物数据完整。
- 检测血浆蛋白CCL13、CCL17、CCL18、CXCL13、CXCL14、COMP、IL-13、MMP3、MMP7、骨桥蛋白、骨膜蛋白和YKL40。
- 主要分析基线生物标志物浓度与12个月FVC%pred绝对变化的关联(安慰剂组)。
主要发现
- 测试队列安慰剂组中,CCL13、CCL18、COMP、CXCL13、CXCL14、骨膜蛋白和YKL40对进展结局有预后价值。
- 无论基线生物标志物浓度高低,吡非尼酮治疗获益一致。
关键数值与推荐
- 预测效应量计算为高与低生物标志物亚组间FVC%pred治疗效应差值(第48周或第52周)。
临床怎么用
- CCL18可作为IPF疾病进展的潜在预后生物标志物,辅助临床风险评估。
- 吡非尼酮治疗决策无需依据基线生物标志物浓度分层。
局限性
- 为事后分析,结果需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heterogeneity in the progression of idiopathic pulmonary fibrosis (IPF) might reflect diversity in underlying pathobiology, and represents a major challenge in the prediction of clinical progression and treatment benefit. Previous studies have found peripheral blood concentrations of several protein biomarkers to be prognostic for overall survival duration in patients with IPF, but these findings have generally not been directly compared and replicated between cohorts. We aimed to use the pivotal trials for pirfenidone to evaluate prognostic and predictive properties of biomarkers across multiple endpoints, and whether they are modulated by pirfenidone treatment. METHODS: We did post-hoc analyses of test and replication cohorts from CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), and ASCEND (NCT01366209) trials for the plasma proteins CCL13, CCL17, CCL18, CXCL13, CXCL14, COMP, interleukin 13, MMP3, MMP7, osteopontin, periostin, and YKL40. Eligible participants had IPF and received pirfenidone 2403 mg/day or placebo in CAPACITY (test cohort) or ASCEND (replication cohort), were aged 40-80 years, and without missing biomarker data at baseline. To identify biomarkers that were consistently prognostic for clinical outcome measures, the primary analysis was the association between biomarker concentrations at baseline and absolute change in percentage of predicted forced vital capacity (FVC%pred) at 12 months (CAPACITY week 48, ASCEND week 52) in the placebo group. Biomarkers within the test cohort that met predefined success criteria of a prognostic p value less than 0·10 from multivariate analysis were further assessed in the replication cohort. Furthermore, the predictive effect size (ie, biomarkers that were predictive for benefit from pirfenidone) was calculated as the difference in FVC%pred treatment effect (pirfenidone in relation to placebo) between high versus low biomarker subgroups at week 48 (test cohort) or week 52 (replication cohort). FINDINGS: Several baseline biomarkers (CCL13, CCL18, COMP, CXCL13, CXCL14, periostin, and YKL40) were prognostic for progression outcomes in the placebo groups of the test cohort. However, only CCL18 was consistently prognostic for absolute change in percentage of FVC%pred in both the test (p=0·032) and replication (p=0·004) cohorts. Pirfenidone treatment benefit was consistent regardless of baseline biomarker concentration. INTERPRETATION: Blood CCL18 concentrations were the most consistent predictor of disease progression across IPF cohorts with potential to inform new target discovery and clinical trial design. Future validation of these findings in prospective studies is warranted. FUNDING: Genentech Inc.
引用
- Neighbors M, Cabanski CR, Ramalingam TR, et al. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respir Med. 2018. PMID: 30072107. doi:10.1016/S2213-2600(18)30185-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。